INTRATUMORAL EXPRESSION OF PD-1/PD-L1 IMMUNE CHECKPOINT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

被引：0

作者：

Baquerizo, Angeles ^{[1
,2
]}

Vavinskaya, Vera ^{[3
]}

Rojas, Angela ^{[4
]}

Mhoyan, Anna ^{[5
]}

Romero-Gomez, Manuel ^{[6
]}

Sher, Linda ^{[7
]}

Madani, Bahar ^{[2
]}

Fisher, Jonathan ^{[1
]}

Schaffer, Randolph ^{[1
]}

Frenette, Catherine T. ^{[8
]}

Marsh, Christopher ^{[9
]}

机构：

[1] Scripps Hlth, Surg, La Jolla, CA USA

[2] Scripps Clin, La Jolla, CA 92037 USA

[3] UCSD, Pathol, La Jolla, CA USA

[4] Virgen Del Rocio Univ Hosp, Hepatol, Seville, Spain

[5] Kaiser, Pathol, San Diego, CA USA

[6] Virgen Del Rocio Univ Hosp, Seville, Spain

[7] USC, Los Angeles, CA USA

[8] Scripps Hlth, Scripps Clin, La Jolla, CA USA

[9] Scripps Hlth, La Jolla, CA USA

来源：

HEPATOLOGY | 2019年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

321

引用

页码：206A / 206A

页数：1

共 50 条

[21] Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis
Ma, K.
Guo, Y.
Wang, Y.
Wang, X.
Xu, Y.
Sun, C.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S584 - S584
[22] Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
Iosune Baraibar
Ignacio Melero
Mariano Ponz-Sarvise
Eduardo Castanon
Drug Safety, 2019, 42 : 281 - 294
[23] Immunohistochemistry of Immune Checkpoint Markers PD-1 and PD-L1 in Prostate Cancer
Sharma, Meenal
Yang, Qi
Mcmahon, Loralee
Miyamoto, Hiroshi
LABORATORY INVESTIGATION, 2019, 99
[24] Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma
Owen, Dwight
Chu, Benjamin
Lehman, Amy M.
Annamalai, Lakshmanan
Yearley, Jennifer H.
Shilo, Konstantin
Otterson, Gregory A.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : 1204 - 1212
[25] PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, Andreas D.
Taran, Florin-Andrei
Wallwiener, Markus
Walter, Christina B.
Kraemer, Bernhard
Grischke, Eva-Maria
Brucker, Sara Y.
BREAST CARE, 2016, 11 (06) : 385 - 390
[26] Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
Baraibar, Iosune
Melero, Ignacio
Ponz-Sarvise, Mariano
Castanon, Eduardo
DRUG SAFETY, 2019, 42 (02) : 281 - 294
[27] Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction
Le Biannic, Raphael
Magnez, Romain
Klupsch, Frederique
Leleu-Chavain, Natascha
Thiroux, Bryan
Tardy, Morgane
El Bouazzati, Hassiba
Dezitter, Xavier
Renault, Nicolas
Vergoten, Gerard
Bailly, Christian
Quesnel, Bruno
Thuru, Xavier
Millet, Regis
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 236
[28] Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
Sharma, Meenal
Yang, Zhiming
Miyamoto, Hiroshi
MEDICINE, 2019, 98 (38)
[29] Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy
Song, Yue
Li, Zhaoming
Xue, Weili
Zhang, Mingzhi
IMMUNOTHERAPY, 2019, 11 (06) : 515 - 529
[30] PD-1/PD-L1 checkpoint in hematological malignancies
Annibali, O.
Crescenzi, A.
Tomarchio, V.
Pagano, A.
Bianchi, A.
Grifoni, A.
Avvisati, G.
LEUKEMIA RESEARCH, 2018, 67 : 45 - 55

← 1 2 3 4 5 →